{"nctId":"NCT00033293","briefTitle":"Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma","startDateStruct":{"date":"2004-03-15","type":"ACTUAL"},"conditions":["Localized Resectable Neuroblastoma","Localized Unresectable Neuroblastoma","Regional Neuroblastoma","Stage 4 Neuroblastoma","Stage 4S Neuroblastoma"],"count":53,"armGroups":[{"label":"Arm I (chemotherapy, immunoglobulin therapy)","type":"EXPERIMENTAL","interventionNames":["Drug: Cyclophosphamide","Other: Laboratory Biomarker Analysis","Procedure: Magnetic Resonance Imaging","Drug: Prednisone","Biological: Therapeutic Immune Globulin"]},{"label":"Arm II (chemotherapy, observation)","type":"ACTIVE_COMPARATOR","interventionNames":["Other: Clinical Observation","Drug: Cyclophosphamide","Other: Laboratory Biomarker Analysis","Procedure: Magnetic Resonance Imaging","Drug: Prednisone"]}],"interventions":[{"name":"Clinical Observation","otherNames":["observation"]},{"name":"Cyclophosphamide","otherNames":["(-)-Cyclophosphamide","2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate","Carloxan","Ciclofosfamida","Ciclofosfamide","Cicloxal","Clafen","Claphene","CP monohydrate","CTX","CYCLO-cell","Cycloblastin","Cycloblastine","Cyclophospham","Cyclophosphamid monohydrate","Cyclophosphamide Monohydrate","Cyclophosphamidum","Cyclophosphan","Cyclophosphane","Cyclophosphanum","Cyclostin","Cyclostine","Cytophosphan","Cytophosphane","Cytoxan","Fosfaseron","Genoxal","Genuxal","Ledoxina","Mitoxan","Neosar","Revimmune","Syklofosfamid","WR- 138719"]},{"name":"Laboratory Biomarker Analysis","otherNames":[]},{"name":"Magnetic Resonance Imaging","otherNames":["Magnetic Resonance","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging"]},{"name":"Prednisone","otherNames":[".delta.1-Cortisone","1, 2-Dehydrocortisone","Adasone","Cortancyl","Dacortin","DeCortin","Decortisyl","Decorton","Delta 1-Cortisone","Delta-Dome","Deltacortene","Deltacortisone","Deltadehydrocortisone","Deltasone","Deltison","Deltra","Econosone","Lisacort","Meprosona-F","Metacortandracin","Meticorten","Ofisolona","Orasone","Panafcort","Panasol-S","Paracort","Perrigo Prednisone","PRED","Predicor","Predicorten","Prednicen-M","Prednicort","Prednidib","Prednilonga","Predniment","Prednisone Intensol","Prednisonum","Prednitone","Promifen","Rayos","Servisone","SK-Prednisone"]},{"name":"Therapeutic Immune Globulin","otherNames":["BayGam","Gamimune N","Gamma Globulin","Gammagard S/D","Gammar-P","IgIV","Immune Globulin","Immune Globulin Intravenous","Immune Globulin IV","Iveegam EN","Panglobulin","Panzyga","Polygam S/D","Sandoglobulin","Therapeutic Immunoglobulin","Venoglobulin-I","Venoglobulin-S","WinRho SDF"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Newly diagnosed neuroblastoma (NBL) or ganglioneuroblastoma with tumor-associated opsoclonus-myoclonus-ataxia syndrome (OMA)\n\n  * Patients with NBL diagnosed within 6 months of OMA diagnosis AND patients with OMA diagnosed within 6 months of NBL diagnosis are eligible\n  * Must enroll on study within 4 weeks of diagnosis\n  * Presence of opsoclonus, myoclonus, and/or ataxia associated with neuroblastoma considered eligible\n* Currently enrolled on COG neuroblastoma protocols: COG-ANBL00B1 or its successor\n* Creatinine clearance or radioisotope GFR ≥ 70 mL/min OR serum creatinine based on age/gender as follows:\n\n  * ≤ 0.4 mg/dL (for patients 1 to 5 months of age)\n  * ≤ 0.5 mg/dL (for patients 6 to 11 months of age)\n  * ≤ 0.6 mg/dL (for patients 1 year of age)\n  * ≤ 0.8 mg/dL (for patients 2 to 5 years of age)\n  * ≤ 1.0 mg/dL (for patients 6 to 9 years of age)\n  * ≤ 1.2 mg/dL (for patients 10 to 12 years of age)\n  * ≤ 1.4 mg/dL (for female patients ≥ 13 years of age)\n  * ≤ 1.5 mg/dL (for male patients 13 to 15 years of age)\n  * ≤ 1.6 mg/dL (for male patients ≥ 16 years of age)\n* No prior IV gamma globulin therapy\n* No prior chemotherapy\n* Concurrent chemotherapy allowed\n* No prior prednisone or corticotropin\n\n  * Patients who have received ≤ 14 days of steroids are eligible\n* Concurrent surgery allowed","healthyVolunteers":false,"sex":"ALL","maximumAge":"8 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Responders","description":"A multi-stage design followed by a test of proportions between the treatment arms (chemo vs. chemo + therapeutic immune globulin (IVIG)) will be performed. The first stage of the multi-stage design will also function as an early stopping rule for insufficient activity of chemotherapy in OMA.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Motor Coordination as Assessed by Neurological Examination and Vineland Adaptive Behavior Scale (VABS)","description":"The \"best\" score at the two time points will be used in this analysis. For a given patient, this \"best\" score will be used to calculate the change from baseline. The mean change from baseline for each treatment group will be calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.53","spread":"115.91"},{"groupId":"OG001","value":"144.73","spread":"110.69"}]}]}]},{"type":"SECONDARY","title":"Functional Outcome as Assessed by Age-appropriate Neuropsychological Testing","description":"The Bayley Scales of infant development mental scale \"best\" score of two time points will be used in the analysis. For a given patient, this score will be used to calculate the change from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"117.5","spread":"35.35"},{"groupId":"OG001","value":"100.75","spread":"25.76"}]}]}]},{"type":"SECONDARY","title":"Biology of Neuroblastoma Associated Opsoclonus-myoclonus-ataxia (OMA) Syndrome Specifically by MRI Findings, Anti-neuronal Antibodies, Cerebrospinal Fluid (CSF) Findings and Tumor Biology","description":"Descriptive analyses on biologic variables will be performed","classes":[]},{"type":"SECONDARY","title":"Long-term Prognosis for Neurologic Recovery by Neurological Examination","description":"A t-test will be performed on the results of each neurologic test, comparing patients who have had disappearance of anti-neural antibodies to patients whose anti-neural antibodies have not disappeared.","classes":[]},{"type":"SECONDARY","title":"Tumor Outcome in Terms of Event-free Survival (EFS) Rate Defined as a Relapse or Progression of Neuroblastoma, a Second Malignancy, or Death","description":"EFS rate for neuroblastoma event from time of study enrollment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.3","spread":null},{"groupId":"OG001","value":"96.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Tumor Outcome in Terms of Overall Survival (OS) Rate","description":"OS rate from time of study enrollment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"96.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":26},"commonTop":["11400-Agitation","58700-Nystagmus","87900-Vomiting(targeted toxicity)","44800-Infections and infestations - Other specify","13200-Anemia"]}}}